Repligen Corp
NASDAQ:RGEN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
119.79
208.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Repligen Corp
Repligen Corp
Other Current Liabilities
Repligen Corp
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Repligen Corp
NASDAQ:RGEN
|
Other Current Liabilities
$28.5m
|
CAGR 3-Years
13%
|
CAGR 5-Years
36%
|
CAGR 10-Years
38%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Other Current Liabilities
$2.7B
|
CAGR 3-Years
23%
|
CAGR 5-Years
23%
|
CAGR 10-Years
15%
|
|
|
Danaher Corp
NYSE:DHR
|
Other Current Liabilities
$1.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Other Current Liabilities
$431.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Other Current Liabilities
$524m
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Other Current Liabilities
$2.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
Repligen Corp
Glance View
Repligen Corp., a prominent player in the bioprocessing industry, has carved out a niche that centers on providing high-quality bioprocessing solutions for the production of biologics, particularly therapeutic proteins and monoclonal antibodies. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen has transformed itself from a developer of research tools into a critical partner for biopharmaceutical manufacturers. The company is primarily engaged in producing innovative products that enhance the efficiency and effectiveness of biomanufacturing processes. Its offerings range from filtration systems to cell culture media, all designed to accelerate drug development and ensure consistent product quality. Through strategic acquisitions and partnerships, Repligen has expanded its portfolio and technological capabilities, positioning itself as a leading provider in a high-demand market driven by the growing need for biologic therapies. For investors, Repligen represents a compelling opportunity rooted in its impressive growth trajectory and strong financial performance. The company has consistently reported rising revenues, bolstered by the increasing global demand for biologics and bioprocessing innovations. Repligen’s continuous investment in research and development ensures that it remains at the forefront of technological advancements, while its robust customer base includes some of the world’s leading pharmaceutical and biotech companies. With a strong balance sheet and a commitment to operational excellence, Repligen is poised for sustainable growth in an industry that is expected to expand significantly over the coming years. For those seeking exposure to the booming biopharmaceutical sector, Repligen offers a unique position that balances innovation, growth potential, and strategic leadership.
See Also
What is Repligen Corp's Other Current Liabilities?
Other Current Liabilities
28.5m
USD
Based on the financial report for Jun 30, 2024, Repligen Corp's Other Current Liabilities amounts to 28.5m USD.
What is Repligen Corp's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
38%
Over the last year, the Other Current Liabilities growth was -19%. The average annual Other Current Liabilities growth rates for Repligen Corp have been 13% over the past three years , 36% over the past five years , and 38% over the past ten years .
You don't have any saved screeners yet
